Advancing Bioanalytical Method Validation: A Comprehensive ICH M10 Approach for Validating LC-MS/MS to Quantify Fluoxetine in Human Plasma and Its Application in Pharmacokinetic Studies.
Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Aimen El OrcheLaboratory of Drugs Sciences, Biomedical Research and Biotechnology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, B.P. 9154, Casablanca 20250, Morocco.ORCID 0000-0001-5352-2476
Amine CheikhCenter for Bioequivalence Studies of the Sheikh Zaid Foundation, Av. Allal Al Fassi, Rabat 10000, Morocco.
Choukri El KhabbazCenter for Bioequivalence Studies of the Sheikh Zaid Foundation, Av. Allal Al Fassi, Rabat 10000, Morocco.
Houda BouchafraLaboratory of Drugs Sciences, Biomedical Research and Biotechnology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, B.P. 9154, Casablanca 20250, Morocco.
My El Abbes FaouziLaboratory of Pharmacology and Toxicology, Biopharmaceutical and Toxicological Analysis Research Team, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10000, Morocco.
Yahya CherrahCenter for Bioequivalence Studies of the Sheikh Zaid Foundation, Av. Allal Al Fassi, Rabat 10000, Morocco.
Siddique Akber AnsariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0003-3966-2282
Hamad M AlkahtaniDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-6983-8587
Shoeb Anwar AnsariDepartment of Drug Science and Technology, University of Turin, 10124 Turin, Italy.
Mustapha BouatiaLaboratory of Analytical Chemistry, Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10000, Morocco.
Funding
Researchers Supporting Project number (RSPD2024R930), King Saud University, Riyadh, Saudi Arabia RSPD2024R930
6 · The paper itself
Abstract
A fast and sample cleanup approach for fluoxetine in human plasma was developed using protein precipitation coupled with LC-MS-MS. Samples were treated with methanol prior to LC-MS-MS analysis. Chromatographic separation was performed on a reverse phase column with an isocratic mobile phase of methanol and 10 mM ammonium formate pH acidified with formic acid (80:20,
Indexed as
FluoxetineTandem Mass SpectrometryChromatography, LiquidHumansLimit of DetectionLiquid Chromatography-Mass SpectrometryMaleReproducibility of ResultsFluoxetinebioanalysisfluoxetineLC-MS-MSpharmacokinetics applicationvalidation
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.